Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 22, 1999, Pages 23-28

  Sheehan, David V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; PLACEBO; VENLAFAXINE; DIAZEPAM; FLUOXETINE; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE;

ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; HUMAN; META ANALYSIS; OBSESSION; PANIC; PRIORITY JOURNAL; SOCIAL PHOBIA; SUSTAINED RELEASE PREPARATION; COMORBIDITY; CONTROLLED DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; REVIEW; SOMNOLENCE; AMBULATORY CARE; ANXIETY DISORDER; DELAYED RELEASE FORMULATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; STATISTICS;

AMBULATORY CARE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; BUSPIRONE; CLINICAL TRIALS; COMORBIDITY; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; HUMANS; PSYCHIATRIC STATUS RATING SCALES;

EID: 0033369418     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lecrubier Y, Hergueta T. Differences between prescription and consumption of antidepressants and anxiolytics. Int Clin Psychopharmacol 1998; 13(suppl 2):S7-S11
2. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990;12:355-362
3. Johnson MR, Emmanuel N, Crawford M, et al. Treatment of generalized anxiety disorder with venlafaxine: a series of 11 cases. J Clin Psychopharmacol 1998;18:418-419
4. Geracioti TD Jr. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-410
5. Papp LA, Sinha SS, Martinez JM, et al. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 1998;34:207-209
6. Pollack MH, Worthington JJ III, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-670
7. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31: 767-771
8. Ananth J, Burgoyne K, Smith M, et al. Venlafaxine for treatment of obsessive-compulsive disorder [letter]. Am J Psychiatry 1995;152:1832
9. Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine. Am J Psychiatry 1996;153:576-577
10. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder [letter]. Arch Gen Psychiatry 1996;53:653-654
11. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine [letter]. J Clin Psychopharmacol 1990;10:152-153
12. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases [letter]. J Clin Psychopharmacol 1996;16:81-84
13. Ninan PT, Knight B, Kirk L, et al. A controlled trial of venlafaxine in trichotillomania: interim phase I results. Psychopharmacol Bull 1998;34: 221-224
14. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995;15:819-844
15. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990;147:1209-1215
16. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19-25
17. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62
18. Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60:22-28
19. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998;18:136-144
20. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry 1991;148:1512-1517
21. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
22. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50: 884-895
23. Haskins T, Rudolph R, Pallay A, et al. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD). Presented at the 21st meeting of the Collegium International Neuro-Psychopharmacologicum: July 12-16, 1998; Glasgow, Scotland
24. Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-535
25. Haskins JT, Rudolph R, Aguiar L, et al. Venlafaxine XR is an efficacious short-and long-term treatment for generalized anxiety disorder. Presented at the 11th annual meeting of the European College of Neuropsychopharmacology: Oct 31-Nov 4, 1998; Paris, France
26. Hackett D, Parks V, Salinas E. A 6 month evaluation of 3 dose levels of venlafaxine extended-release in non-depressed outpatients with generalized anxiety disorder. Presented at the 19th annual conference of the Anxiety Disorders Association of America; March 25-28, 1999; San Diego, Calif